New drug AGX101 targets Hard-to-Treat cancers in early trial

NCT ID NCT06440005

First seen Feb 14, 2026 · Last updated May 14, 2026 · Updated 9 times

Summary

This study tests a new drug called AGX101 in people with advanced solid tumors that have not responded to standard treatments. The drug is given through a vein and aims to shrink or control tumors. The main goals are to find the safest dose and understand side effects. About 80 participants will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Florida Cancer Specialist

    RECRUITING

    Sarasota, Florida, 34232, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Oncology

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Email: •••••@•••••

    Contact

  • NEXT Oncology

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

    Contact Phone: •••-•••-••••

  • Sarah Cannon Research Center

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact

    Contact Email: •••••@•••••

  • USC/Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

    Contact

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.